MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...

MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to ...

The pharmaceutical giant raised its full-year guidance for the third time this year after higher third-quarter profit and ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

全球与中国司库奇尤单抗注射液市场运营态势及前景预测研究报告2024-2030年 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 2.1 全球司库奇尤单抗注射液总体市场规模：2023 VS 2030 ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its ...

Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its ...

When I (Kody) last covered Novartis with a buy rating in May, I liked its continuity as a business. The company's product portfolio and pipeline were also impressive. Novartis' balance sheet was ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...